Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

S&P Pharmaceuticals SPDR (XPH)

$37.71 0.49 (1.33%)

20:00 EDT XPH Stock Quote Delayed 15 Minutes

Volume:

Previous Close $37.71

Market Cap 288.45M

PE Ratio -

EPS -

Volume (Avg. Vol.) 182,100

Day's Range 37.22 - 37.86

52-Week Range 34.37 - 46.05

Dividend & Yield 0.24 (0.64%)

XPH Stock Predictions, Articles, and S&P Pharmaceuticals SPDR News

From InvestorPlace
From the Web

3 Healthcare ETFs to Sell Amid Political Headwinds

By Todd Shriber, InvestorPlace Contributor Apr 23, 2019

While the rest of the market continues upward, the healthcare sector -- and healthcare ETFs -- continue to struggle.

5 Best-Performing Sector ETFs of July

By Zacks Investment Research Aug 2, 2018

We have highlighted sector ETFs that witnessed handsome gains last month and could be better plays in the months ahead should the trends prevail. Compare Broker....

7 Best Healthcare ETFs for the Rest of 2018

By Todd Shriber, InvestorPlace Contributor Mar 8, 2018

Some of the best healthcare ETFs to buy are more "traditional", while others focus on very specific areas of the industry. These seven healthcare ETFs should deliver for investors over the remainder of 2018.

What Lies in Store for Pharma ETFs?

By Zacks Investment Research Nov 27, 2017

Pharma stocks have done well this year; what lies ahead?

When You Exit the Market, Don’t Let The Door Hit You On Your Way Out

By Gary Gordon, President, Pacific Park Financial May 18, 2016

You cannot make this stuff up. The median stock in the S&P 500 has never been more overvalued on these key metrics. Now's the time for caution...

3 “Happy New Year” ETFs to Buy for Huge Growth

By Johnson Research Group Dec 22, 2015

Unwarranted bearishness and strong technicals make these three ETFs good bets for the New Year.

Compare Brokers

FDA OK'd record number of generic drugs in F19

From Seeking Alpha Oct 16, 2019

The FDA announces that it approved 1,171 generic medicines in fiscal 2019 (12-month period ended September 30), a record total from the previous all-time high of 971 in fiscal 2018. The total consiste

'Fast Money Halftime Report' Picks For September 25

From Benzinga Sep 25, 2019

On CNBC's "Fast Money Halftime Report," Joe Terranova said that JPMorgan Chase & Co. (NYSE: JPM) is going to trade higher, toward$125. Meghan Shue is a...

SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.0839

From Seeking Alpha Sep 23, 2019

SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) declares quarterly distribution of $0.0839.30-Day SEC Yield of 1.00% as of Sep 19.Payable Sep 26; for shareholders of record Sep 24; ex-div Sep 23.Press

Health-Care Stocks Are Worth a Look Despite Worry Over Price Regulation, Analyst Says

From Barron's Sep 12, 2019

The sector has lagged behind the broader market, partly because of concern that the government could act to rein in drug prices.

Bristol-Myers Squibb Stock Has Upside — But Mind the Risks

From InvestorPlace Aug 12, 2019

Bristol-Myers Squibb stock touched a multi-year low last month. But the BMY stock price is cheap enough now to take on real risks.

Buy Amgen and Gilead Stock as Bitoech Returns to ‘Stability and Growth’

From Barron's May 23, 2019

Biotech has held up better than some other areas of the health-care sector this year, although the industry has still mostly lagged the broader market. Citigroup says it is time to buy.

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!